Altan, the pharmaceutical company of hospital injectable generics, announces the launch of Tobramycin in Spain, an inhalation antibiotic used in the treatment of pulmonary infections by Pseudomonas.

Madrid, 4th of March 2020

Altan Pharmaceuticals, the Spanish subsidiary of Altan Pharma Ltd., a company dedicated to the development, manufacture and marketing of injectable medicines for hospital use, is pleased to announce the launch of the generic formulation of the antibiotic Tobramycin for inhalation.

Tobramycin is indicated for patients of 6 years of age or older with cystic fibrosis (CF) for long-term treatment of chronic lung infections due to Pseudomonas aeruginosa. Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts mainly by interfering protein synthesis, which leads to the alteration of the permeability of the cell membrane, the progressive rupture of the cell cover and the eventual death of the cell. It is bactericidal at equal concentrations or slightly higher than inhibitory concentrations.

“The addition of Tobramycin to our already extensive portfolio of anti-infectives including anti-viral, anti-fungal and antibiotic agents, increases our commitment to helping healthcare professionals fight against infections. In addition to inhaled Colistimethate, Tobramycin perfectly complements the treatment of bronchiectasis and cystic fibrosis by increasing the therapeutic arsenal to treat infections with Pseudomonas aeruginosa” said Guillermo Herrera, president of Altan Pharma.

About Altan

Altan Pharma LTD is a specialty pharmaceutical company that develops, manufactures and markets injectable medications for the hospital and other provider segments. The company was founded with the strategic objective of building a premier, global injectable drug company that is committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers.

Altan’s product portfolio includes a range of pain, anti-infective and other medications available in a variety of presentations including premix bags, liquid and lyophilized vials, and ampoules.

Altan has presence in Europe, Latin America, Asia, Africa and Australia